È necessario avere un abbonamento a JoVE per visualizzare questo. Accedi o inizia la tua prova gratuita.
Method Article
In this study the expression of a target human recombinant protein in different production platforms was compared. We focused on traditional fermenter-based cultures and on plants, describing the set-up of each system and highlighting, on the basis of the reported results, the inherent limits and advantages for each platform.
Sistemi a base vegetale sono considerati una valida piattaforma per la produzione di proteine ricombinanti come risultato della loro potenziale ben documentata per la produzione flessibile, a basso costo di alta qualità, prodotti bioattivi.
In questo studio, abbiamo confrontato l'espressione di una proteina ricombinante umana bersaglio nelle culture tradizionali basati fermentatori cellule (batteriche e insetti) con sistemi di espressione a base vegetale, sia transitori e stabili.
Per ogni piattaforma, abbiamo descritto il set-up, ottimizzazione e durata del processo di produzione, la qualità del prodotto finale e le rese e abbiamo valutato i costi di produzione provvisori, specifici per la proteina ricombinante bersaglio selezionato.
Nel complesso, i nostri risultati indicano che i batteri non sono adatti per la produzione della proteina bersaglio a causa della sua accumulo all'interno corpi di inclusione insolubili. D'altro canto, i sistemi a base vegetale sono piattaforme versatili tcappello permettono la produzione della proteina selezionato a bassi costi di-Baculovirus / sistema cellulare di insetto. In particolare, le linee transgeniche stabili visualizzati il massimo rendimento del prodotto finale e le piante che esprimono transitori sviluppo del processo più veloce. Tuttavia, non tutte le proteine ricombinanti possono beneficiare di sistemi a base vegetale, ma la migliore piattaforma di produzione dovrebbero essere determinati empiricamente con un approccio caso per caso, come descritto qui.
Recombinant proteins are commercially mass-produced in heterologous expression systems with the aid of emerging biotechnology tools. Key factors that have to be considered when choosing the heterologous expression system include: protein quality, functionality, process speed, yield and cost.
In the recombinant protein field, the market for pharmaceuticals is expanding rapidly and, consequently, most biopharmaceuticals produced today are recombinant. Proteins can be expressed in cell cultures of bacteria, yeasts, molds, mammals, plants and insects, as well as in plant systems (either via stable- or transient-transformation) and transgenic animals; each expression system has its inherent advantages and limitations and for each target recombinant protein the optimal production system has to be carefully evaluated.
Plant-based platforms are arising as an important alternative to traditional fermenter-based systems for safe and cost-effective recombinant protein production. Although downstream processing costs are comparable to those of microbial and mammalian cells, the lower up-front investment required for commercial production in plants and the potential economy of scale, provided by cultivation over large areas, are key advantages.
We evaluated plants as bioreactors for the expression of the 65 kDa isoform of human glutamic acid decarboxylase (hGAD65), one of the major autoantigen in Type 1 autoimmune diabetes (T1D). hGAD65 is largely adopted as a marker, both for classifying and monitoring the progression of the disease and its role in T1D prevention is currently under investigation in clinical trials. If these trials are successful, the global demand for recombinant hGAD65 will increase dramatically.
Here, we focus on the expression of the enzymatically inactive counterpart of hGAD65, hGAD65mut, a mutant generated by substituting the lysine residue that binds the cofactor PLP (pyridoxal-5'-phosphate) with an arginine residue (K396R)1.
hGAD65mut retains its immunogenicity and, in plant and insect cells, accumulates up to ten-fold higher than hGAD65, its wild-type counterpart. It was hypothesized that the enzymatic activity of hGAD65 interferes with plant cell metabolism to such an extent that it suppresses its own synthesis, whereas hGAD65mut, the enzymatically-inactive form, can be accumulated in plant cells to higher levels.
For the expression of hGAD65mut, the use of different technologies, widely used in plant biotechnology, was explored here and compared to traditional expression platforms (Escherichia coli and Baculovirus/insect cell-based).
In this work, the recombinant platforms developed for the expression of hGAD65mut comprising traditional and plant-based systems were reviewed and compared on the basis of process speed and yield, and of final product quality and functionality.
1. Costruzione di vettori di espressione
2. Recombinant Protein Expression
3. Analisi Recombinant Protein Expression
Un disegno sperimentale per l'espressione eterologa di una proteina ricombinante bersaglio in diversi sistemi di produzione è descritto qui. Il primo obiettivo è stato il set-up di diverse piattaforme stabilendo le condizioni ottimali per l'espressione della proteina bersaglio in ciascun sistema.
L'espressione della proteina bersaglio, hGAD65mut, è stata indotta in triplicato E. culture coli. Dopo 3 ore di espressione a 37 ° C, le cellule batteriche sono sta...
In questo studio sono stati confrontati tre piattaforme diverse per l'espressione di una proteina ricombinante umana: cellule batteriche, cellule Baculovirus / insetti e piante. La piattaforma a base vegetale è stato esaminato ulteriormente sfruttando le tre tecnologie di espressione ampiamente utilizzati (cioè transitoria - MagnICON e pK7WG2 basati - e stabili). La proteina bersaglio scelto per questo esperimento, hGAD65mut, è stata precedentemente espresso in diversi sistemi 13, e la sua pro...
The authors declare that there is no conflict of interests regarding the publication of this paper.
This work was supported by the COST action ‘Molecular pharming: Plants as a production platform for high-value proteins’ FA0804. The Authors thank Dr Anatoli Giritch and Prof. Yuri Gleba for providing the MagnICON vectors for research purposes.
Name | Company | Catalog Number | Comments |
Yeast extract | Sigma | Y1333 | |
Tryptone | Formedium | TRP03 | |
Agar Bacteriological Grade | Applichem | A0949 | |
Sf-900 II SFM medium | Gibco | 10902-088 | |
Grace’s Insect Medium, unsupplemented | Gibco | 11595-030 | |
Cellfectin II Reagent | Invitrogen | 10362-100 | |
MS medium including vitamins | Duchefa Biochemie | M0222 | |
Sucrose | Duchefa Biochemie | S0809 | |
Plant agar | Duchefa Biochemie | P1001 | |
Ampicillin sodium | Duchefa Biochemie | A0104 | Toxic |
Gentamycin sulphate | Duchefa Biochemie | G0124 | Toxic |
Ganciclovir | Invitrogen | I2562-023 | |
Carbenicillin disodium | Duchefa Biochemie | C0109 | Toxic |
Kanamycin sulfate | Sigma | K4000 | Toxic |
Rifampicin | Duchefa Biochemie | R0146 | Toxic – 25 mg/ml stock in DMSO |
Streptomycin sulfate | Duchefa Biochemie | S0148 | Toxic |
Spectinomycin dihydrochloride | Duchefa Biochemie | S0188 | |
IPTG (isopropil-β-D-1-tiogalattopiranoside) | Sigma | I5502 | Toxic |
MES hydrate | Sigma | M8250 | |
MgCl2 | Biochemical | 436994U | |
Acetosyringone | Sigma | D134406 | Toxic – 0.1 M stock in DMSO |
Syringe (1 ml) | Terumo | ||
MgSO4 | Fluka | 63136 | |
BAP (6-Benzylaminopurine) | Sigma | B3408 | Toxic |
NAA (Naphtalene acetic acid) | Duchefa Biochemie | N0903 | Irritant |
Cefotaxime | Mylan Generics | ||
Trizma base | Sigma | T1503 | Adjust pH with 1 N HCl to make Tris-HCl buffer |
HCl | Sigma | H1758 | Corrosive |
NaCl | Sigma | S3014 | 1 M stock |
KCl | Sigma | P9541 | |
Na2HPO4 | Sigma | S7907 | |
KH2PO4 | Sigma | P9791 | |
PMSF (Phenylmethanesulfonylfluoride) | Sigma | P7626 | Corrosive, toxic |
Urea | Sigma | U5378 | |
β-mercaptoethanol | Sigma | M3148 | Toxic |
Tween-20 | Sigma | P5927 | |
Hepes | Sigma | H3375 | |
DTT (Dithiothreitol) | Sigma | D0632 | Toxic – 1 M stock, store at -20 °C |
CHAPS | Duchefa Biochemie | C1374 | Toxic |
Plant protease inhibitor cocktail | Sigma | P9599 | Do not freeze/thaw too many times |
SDS (Sodium dodecyl sulphate) | Sigma | L3771 | Flammable, toxic, corrosive – 10% stock |
Glycerol | Sigma | G5516 | |
Brilliant Blue R-250 | Sigma | B7920 | |
Isopropanol | Sigma | 24137 | Flammable |
Acetic acid | Sigma | 27221 | Corrosive |
Anti-Glutamic acid decarboxylase 65/67 | Sigma | G5163 | Do not freeze/thaw too many times |
Horseradish peroxidase (HRP)-conjugate anti-rabbit antibody | Sigma | A6154 | Do not freeze/thaw too many times |
Sf9 Cells | Life Technologies | 11496 | |
BL21 Competent E. coli | New England Biolabs | C2530H | |
Protein A Sepharose | Sigma | P2545 | |
Cell culture plates | Sigma | CLS3516 | |
Radio Immuno Assay kit | Techno Genetics | 12650805 | Radioactive material |
Richiedi autorizzazione per utilizzare il testo o le figure di questo articolo JoVE
Richiedi AutorizzazioneThis article has been published
Video Coming Soon